New Federal Contractors — June 23, 2026

Analogic Corp secured a firm-fixed-price delivery order worth $138.3M (potential $499.7M including options) from TSA for full-sized CT systems, under full and open competition with no set-asides, indicating a competitive win and strong market position in detection technology.

Leidos Biomedical Research Inc., a Leidos Holdings subsidiary, won a $121.5M cost-plus-fixed-fee delivery order from NIH NCI for health R&D, with low pricing risk and predictable margins, but the contribution is modest (~$30.4M/year) relative to Leidos' total revenue.

START2 GROUP, INC. secured a $141.3M firm-fixed-price contract with HHS BARDA for biotechnology R&D, but only $2.8M has been outlayed, indicating early-stage milestone-based funding and high pricing risk, with the company being a small, foreign-owned disadvantaged business raising scalability concerns.

START2 GROUP's $141.3M BARDA contract has only $2.8M outlayed, signaling early-stage R&D with milestone-based payments; firm-fixed-price structure amplifies execution risk if costs overrun.

Two of three contracts (START2 GROUP and Leidos Biomedical) are from HHS, representing 65.5% of total obligation ($262.8M), creating civilian-sector concentration risk for any investor exposed to these names.

Analogic Corp's $138.3M TSA contract is firm-fixed-price and vulnerable to continuing resolution (CR) impacts if awarded during CR period; TSA budget continuity is critical for option exercises.

Analogic Corp's competitive win for $138.3M in full-sized CT systems with potential $499.7M total value provides a long-term civilian security growth opportunity; option exercises through 2033 could double revenue from this contract.

Leidos Biomedical Research Inc.'s $121.5M cost-plus NIH contract with low execution risk offers stable cash flows; renewal or follow-on after August 2024 could sustain this revenue stream.

START2 GROUP, INC., though self-certified as a small disadvantaged business, may benefit from future set-aside opportunities at HHS/BARDA if it successfully executes this early-stage $141.3M contract.

Two contracts (START2 GROUP and Leidos Biomedical) totaling $262.8M from HHS underscore sustained federal investment in biodefense and vaccine research, with BARDA and NIH providing long-duration awards despite execution risks.

Analogic Corp's $138.3M TSA contract for full-sized CT systems reflects a multi-year cycle of advanced screening technology deployment, with potential total value of $499.7M through 2033, signaling a strong secular trend in aviation security.

{"entity"=>"Analogic Corp", "reason"=>"Secured $138.3M TSA CT contract with potential $499.7M total; long-term revenue visibility but firm-fixed-price risk and CR vulnerability.", "trigger"=>"TSA option exercise announcements; quarterly earnings recognition of contract revenue; DHS budget appropriations for FY2027"}

{"entity"=>"START2 GROUP, INC.", "reason"=>"High-risk, early-stage $141.3M BARDA contract with only $2.8M outlayed; execution and scalability concerns dominate.", "trigger"=>"Quarterly outlay update filings; contract modification announcements; small business status verification"}

{"entity"=>"Leidos Holdings, Inc.", "reason"=>"$121.5M NIH contract ending August 2024; renewal or re-compete outcome will determine sustainability of ~$30.4M annual revenue stream.", "trigger"=>"Contract expiration (August 2024); NIH solicitation for follow-on contracts; option exercise on remaining $4.3M"}